An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, gastrointestinal, and neurological systems will be assessed.

Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).

Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS) (normal luminance and low luminance visual acuity)

Changes in Slit lamp biomicroscopy assessed by the physician will be assessed.

Measured by using Goldmann applanation tonometry (GAT) or hand-held tonometer

Changes in Lens examination assessed by the physician will be assessed.

Changes in Ophthalmoscopy assessed by the physician will be assessed.

Fundus autofluorescence (FAF) imaging assessed by Investigator

Measured by color fundus photography (CFP) imaging assessed by Investigator

Spectral domain optical coherence tomography (SD-OCT)

Fluorescein angiography (FA) assessed by Investigator

Choroidal Neovascularization (CNV) assessed by Investigator.

Post-treatment Administration Assessment (study eye only)

Cmax of ABBV-6628

Tmax of ABBV-6628

AUC0-Tlast of ABBV-6628

Ctrough of ABBV-6628